SLC5A2 and diabetic kidney disease: A transcriptomic analysis of plasma biomarkers from T2DM patients treated for 2 years with canagliflozin concerning those treated with glimepiride showed a decrease of genes encoding TNF receptor 1, IL-6, matrix metalloproteinase 7, and fibronectin 1, suggesting that SGLT2 inhibition may attenuate molecular processes typically related to DKD progression, such as inflammation, ECM turnover, and fibrosis [312].